Retatrutide · adverse-event profile · research use only
Retatrutide side effects, as the trials actually reported them.
The most-searched question about retatrutide (LY3437943) is what its side effects look like — and unlike most research peptides, the answer is documented, not guessed. The Phase 2 obesity trial (Jastreboff et al., NEJM 2023) and the pivotal Phase 3 program published the full adverse-event tables, dose by dose. This page reproduces those findings as a research reference: the gastrointestinal events that dominate, how tightly they track dose, why they concentrate in the titration weeks, and the cardiovascular and sensory signals worth knowing. It is a summary of clinical-trial data, not a human-use protocol or medical advice.
GI events dominate the profile
Across the trials the most frequent adverse events were gastrointestinal — nausea, diarrhea, vomiting and constipation — and they occurred more often with retatrutide than placebo. In the pivotal Phase 3 program the 12 mg arm reported nausea ~42%, diarrhea ~32%, constipation ~26% and vomiting ~25%, versus roughly 15%, 14%, 11% and 5% on placebo. They were predominantly mild to moderate in severity. GI tolerability is the single defining feature of the GLP-1 / GIP / glucagon triple-agonist class.
How the class compares →The effect is dose-dependent
Adverse-event rates rise with dose. Phase 3 nausea ran ~29% at 4 mg, ~38% at 9 mg and ~42% at 12 mg; vomiting climbed from ~11% to ~25% across the same steps. A meta-analysis put the relative risk of nausea at about 2.7x placebo at 4 mg and roughly 4x at 8–12 mg, with the sharpest jump between 4 mg and 8 mg. In Phase 2, overall adverse events were reported in 73–94% of retatrutide participants (highest in the 8 and 12 mg arms) versus 70% on placebo — the placebo figure showing how much is dose-driven signal.
See the titration ladder →They cluster in the escalation phase
The GI events were not spread evenly across the study — they occurred primarily during dose escalation, in the first one to two weeks after each step up, and were largely transient. This is why the trials held each titration step for about four weeks and why researchers model a slow ramp rather than starting at the top dose. It ties directly to the ~6-day half-life: steady-state at each step is approached over roughly four to five weeks.
Half-life and cadence →A lower starting dose cut incidence
One of the clearest findings: starting at 2 mg instead of 4 mg significantly reduced GI adverse-event incidence — even when participants ultimately reached the same maintenance dose. In other words, the escalation schedule itself is a tolerability variable, not just a dosing formality. It is the main reason the published titration begins low and steps up in four-week intervals.
Titration reference →Heart rate and dysesthesia signals
Beyond the gut, two non-GI findings recur. Heart rate rose in a dose-dependent way, peaking around week 24 and declining thereafter (roughly 5–10 bpm at higher doses). Dysesthesia — tingling or altered skin sensation, linked to glucagon-receptor activity — appeared in ~5% at 4 mg up to ~12–13% at the top doses versus ~1% on placebo; it was generally mild to moderate and mostly resolved during treatment. Serious adverse events were uncommon and comparable to placebo (about 4% in each group in Phase 2).
View the compound →Research-use framing
Every figure here describes adverse events observed in human clinical trials and is reproduced as a research reference for laboratory and in-vitro modelling — not as a prediction of what any individual would experience, and not as instructions for human use. Retatrutide is an investigational compound with no regulatory approval. Titan supplies it strictly as a research reagent, not for human or animal consumption. Nothing on this page is medical advice.
Research-use policy →The detail, in plain terms
The adverse-event table, at a glance.
Rates below are drawn from the published retatrutide clinical trials (Phase 2 NEJM 2023 and the pivotal Phase 3 program) and reproduced as a research reference. Phase 3 event rates are shown for the 12 mg arm versus placebo; exact figures vary by study and cohort.
- Nausea
- ~42% at 12 mg vs ~15% placebo (Phase 3); dose-related, peaks in escalation, largely transient.
- Diarrhea
- ~32% at 12 mg vs ~14% placebo; usually mild-moderate and short-lived.
- Constipation
- ~26% at 12 mg vs ~11% placebo; can coexist with diarrhea across different participants.
- Vomiting
- ~25% at 12 mg vs ~5% placebo; rises steeply between the 4 mg and 8–9 mg steps.
- Dysesthesia
- ~12–13% at top doses vs ~1% placebo; tingling/altered sensation, mostly resolved during treatment.
- Heart rate
- Dose-dependent rise (~5–10 bpm), peaks ~week 24, declines thereafter.
- Discontinuation (AE)
- ~6–16% across retatrutide arms (Phase 2); ~4–11% Phase 3 — vs ~0–5% placebo.
- Serious AEs
- Uncommon and comparable to placebo (~4% each group, Phase 2).
Questions researchers ask
Before you order.
- What are the most common retatrutide side effects in the research?
- The most frequently reported adverse events in the trials were gastrointestinal: nausea, diarrhea, vomiting and constipation. In the pivotal Phase 3 program the 12 mg arm reported nausea around 42%, diarrhea around 32%, constipation around 26% and vomiting around 25%, all higher than placebo. They were predominantly mild to moderate. These figures come from human clinical trials and are reproduced as a research reference, not as medical advice.
- Are retatrutide's side effects dose-dependent?
- Yes. Adverse-event rates rose consistently with dose across the trials — for example, Phase 3 nausea ran roughly 29% at 4 mg, 38% at 9 mg and 42% at 12 mg, and vomiting climbed from about 11% to 25% across the same steps. A meta-analysis reported the sharpest increase in nausea risk occurring between the 4 mg and 8 mg dose levels.
- When do the side effects happen?
- The gastrointestinal events occurred primarily during dose escalation — typically the first one to two weeks after each step up — and were largely transient. This is why the trials held each titration step for about four weeks, and it aligns with the ~6-day half-life, which means each step approaches steady-state over roughly four to five weeks.
- Did a lower starting dose reduce side effects?
- Yes. The trials found that beginning at 2 mg rather than 4 mg significantly reduced gastrointestinal adverse-event incidence, even when participants ultimately reached the same maintenance dose. The escalation schedule itself acts as a tolerability lever, which is why the published titration starts low and steps up gradually.
- Are there non-gastrointestinal side effects?
- Two recur in the data. Heart rate increased in a dose-dependent manner, peaking around week 24 before declining. Dysesthesia — tingling or altered skin sensation tied to glucagon-receptor activity — appeared in roughly 5% at 4 mg up to about 12–13% at the highest doses, versus about 1% on placebo, and was generally mild to moderate and mostly resolved during treatment. Serious adverse events were uncommon and comparable to placebo.
- Is retatrutide approved for human use?
- No. Retatrutide is an investigational compound with no regulatory approval for human use. Titan Peptide Lab supplies it strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use. The adverse-event data on this page is a summary of published clinical research and is not medical or dosing advice.
Related reading